OptiNose Inc (OPTN)
1.26
-0.03
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
OptiNose Profit Margin (Quarterly): -94.54% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -94.54% |
December 31, 2023 | -50.17% |
September 30, 2023 | -46.88% |
June 30, 2023 | 13.50% |
March 31, 2023 | -159.1% |
December 31, 2022 | -72.64% |
September 30, 2022 | -74.48% |
June 30, 2022 | -94.24% |
March 31, 2022 | -171.6% |
December 31, 2021 | -69.41% |
September 30, 2021 | -78.42% |
June 30, 2021 | -128.0% |
March 31, 2021 | -217.8% |
Date | Value |
---|---|
December 31, 2020 | -146.0% |
September 30, 2020 | -137.4% |
June 30, 2020 | -251.7% |
March 31, 2020 | -408.6% |
December 31, 2019 | -225.6% |
September 30, 2019 | -232.4% |
June 30, 2019 | -410.0% |
March 31, 2019 | -645.1% |
December 31, 2018 | -872.7% |
September 30, 2018 | -1.32K% |
June 30, 2018 | -1.93K% |
March 31, 2018 | -3.53K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-410.0%
Minimum
Jun 2019
13.50%
Maximum
Jun 2023
-152.8%
Average
-132.7%
Median
Profit Margin (Quarterly) Benchmarks
Madrigal Pharmaceuticals Inc | -- |
Viking Therapeutics Inc | -- |
Zevra Therapeutics Inc | -485.3% |
CytomX Therapeutics Inc | 33.26% |
Spero Therapeutics Inc | -301.4% |
Profit Margin (Quarterly) Related Metrics
Return on Assets | -29.88% |
Return on Invested Capital | -63.39% |
Gross Profit Margin (Quarterly) | 91.73% |
Operating Margin (Quarterly) | -54.27% |
Return on Net Operating Assets | -108.9% |